CureVac NV (id:6438 CVAC)
2.99 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/25/2024 9:20:30 PM)
Exchange closed, opens in 12 hours 9 minutes
About CureVac NV
Market Capitalization 643.85M
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
| Headquarters (address) |
Friedrich-Miescher-Strasse 15 Tübingen 72076 Germany |
| Phone | 49 7071 9883 0 |
| Website | https://www.curevac.com |
| Employees | 999 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | CVAC |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 2.22 - 5.28 |
| Market Capitalization | 643.85M |
| P/E trailing | 5.86 |
| P/E forward | -6.52 |
| Price/Sale | 9.78 |
| Price/Book | 1.71 |
| Beta | 2.61 |
| EPS | 3.00 |
| EPS Germany (ID:66, base:318) | 2.39 |